In vivo biodistribution of the radiolabeled compound revealed higher activity uptake in EGFR-positive tumors as compared to previously studied EGFR PET imaging agent candidates, and a remarkable tumor: blood and tumor: muscle activity uptake ratios of about 7 and 5, respectively, three hours following administration of the radiotracer (Table 5). This evidence concerns the gene EGFR and neoplasm.